المؤلفون: Stark JH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Cambridge, Massachusetts, USA., McFadden B; Behavioralize LLC, Wynnewood, Pennsylvania, USA.; The Department of Agricultural Economics and Agribusiness, University of Arkansas, Fayetteville, Arkansas, USA., Patel N; Behavioralize LLC, Wynnewood, Pennsylvania, USA., Kelly PH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, Pennsylvania, USA., Gould LH; Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, New York, New York, USA., Riis J; Behavioralize LLC, Wynnewood, Pennsylvania, USA.

المصدر: Zoonoses and public health [Zoonoses Public Health] 2024 Jun; Vol. 71 (4), pp. 349-358. Date of Electronic Publication: 2024 Jan 04.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Blackwell Verlag Country of Publication: Germany NLM ID: 101300786 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1863-2378 (Electronic) Linking ISSN: 18631959 NLM ISO Abbreviation: Zoonoses Public Health Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/prevention & control , Intention*, Humans ; Adult ; Female ; Male ; United States ; Health Belief Model ; Vaccination/psychology ; Middle Aged ; Health Knowledge, Attitudes, Practice ; Lyme Disease Vaccines ; Young Adult ; Adolescent

مستخلص: Aims: Lyme disease (LD) cases in the United States are estimated to be approaching 500,000 annually. Protective measures, such as repellent use and wearing protective clothing are recommended by public health officials. However, no protective measure has been proven to be consistently effective, partly because they require consistent and persistent behaviour change. While safe and effective vaccines are in development, it is unclear what factors influence the intention to vaccinate against LD. This study uses the Health Belief Model (HBM) framework to determine key drivers associated with vaccine intention. The HBM is widely applied in public health research and uses the following constructs: perceived susceptibility and severity of disease, perceived benefits and barriers to disease prevention, and cues to action for disease prevention to predict health behaviours. To date, the HBM framework has not been applied to vaccination intention for LD.
Methods and Results: Data were collected from 874 adults and 834 caregivers of children residing in US states endemic to LD. Sampling adults and caregivers allows us to explore how the intention to vaccinate differs among those at-risk. Estimates from structural equation modelling (SEM) show that the HBM constructs explain much of the variation in intention to vaccinate against LD. Both adult and caregiver intentions to vaccinate are positively influenced by cues to action, perceived susceptibility of LD, and perceived benefits to vaccination. However, there is variation in the influence of constructs across the samples. Caregiver's intention to vaccinate is positively influenced by the perceived severity of LD and negatively influenced by safety concerns about the vaccine, whereas adult intention is negatively influenced by perceived barriers to vaccination.
Conclusion: A strong relationship of cues to action on vaccine intention in samples of adults and caregivers suggests the importance of a recommendation from a healthcare provider or the Centers for Disease Control and Prevention (CDC).
(© 2024 Pfizer Inc. Zoonoses and Public Health published by Wiley‐VCH GmbH.)

المؤلفون: Pavia CS; Department of Biomedical Sciences, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States.; Division of Infectious Diseases, New York Medical College, Valhalla, NY, United States., Saggio G; Department of Clinical Specialties, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States., Plummer MM; Department of Clinical Specialties, New York Institute of Technology, College of Osteopathic Medicine, Old Westbury, NY, United States.

المصدر: Frontiers in immunology [Front Immunol] 2024 Feb 14; Vol. 14, pp. 1326623. Date of Electronic Publication: 2024 Feb 14 (Print Publication: 2023).

نوع المنشور: Journal Article; Review; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Lyme Disease*/prevention & control , Borrelia burgdorferi* , Borrelia burgdorferi Group*, United States ; Humans ; Lyme Disease Vaccines ; Antibodies, Bacterial

مستخلص: Working together, two major pharmaceutical companies have developed a Lyme disease vaccine consisting of recombinant-derived outer surface protein A (OspA) of the etiologic agent Borrelia burgdorferi . Multiple clinical trials have shown the vaccine to have good safety and efficacy results, and it is hoped that it would become available for human use at least by the year 2025 after receiving approval from the U.S. Food and Drug Administration. There are still challenges left to ensure that the vaccine has, at most, minimal side effects. Also, because the previously developed Lyme disease vaccine was discontinued in 2002 after four years of distribution, due in part, for frivolous reasons having little or no scientific basis, that even led to legal entanglements involving the vaccine manufacturer and some of the medical personnel overseeing the clinical trials, there will be concerns that this newly developed one could be subject again to some of the same unnecessary scrutiny rendering its implementation suboptimal. Initially this review will focus on the key epidemiological, microbiologic, immunologic and clinical aspects of Lyme disease that provide the foundation for developing this type of vaccine that could have a serious impact on the prevalence of this and even certain other tick-transmitted infections.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2024 Pavia, Saggio and Plummer.)

المؤلفون: Gidengil C; RAND Corporation, 20 Park Plaza, Suite 910, Boston, MA 02116, USA. Electronic address: gidengil@rand.org., Scherer AM; University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA., Parker AM; RAND Corporation, 4570 Fifth Ave #600, Pittsburgh, PA 15213, USA., Gedlinske A; University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA., Fleck-Derderian S; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Hinckley AF; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Hook SA; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA., Lindley MC; Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, Immunization Services Division, 1600 Clifton Road, Atlanta, GA 30329, USA., Marx GE; Centers for Disease Control and Prevention, National Centers for Emerging and Zoonotic Infectious Diseases, Division of Vector-Borne Diseases, 3156 Rampart Road, Fort Collins, CO 80521, USA.

المصدر: Vaccine [Vaccine] 2024 Mar 19; Vol. 42 (8), pp. 1899-1905. Date of Electronic Publication: 2024 Feb 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE

مواضيع طبية MeSH: Vaccines* , Lyme Disease*/prevention & control, Child ; Humans ; United States ; Lyme Disease Vaccines ; Intention ; Health Knowledge, Attitudes, Practice ; Parents ; Antibodies, Monoclonal ; Vaccination

مستخلص: Background: Lyme disease (LD) is the most common vector-borne disease in the United States, with increasing incidence and geographic range. Case incidence peaks among school-aged children. New LD preventives are in clinical trials.
Methods: We conducted an online survey of parents of children aged 5-18 years in states with high or emerging incidence of LD. Our primary outcome was willingness ("definitely" or "probably") for their child to receive an LD vaccine. Our secondary outcome was preference for annual monoclonal antibody injections compared to a 3-dose vaccine series with boosters. Analyses were weighted to reflect parent gender, parent race/ethnicity, and child age by state.
Results: Among 1,351 parent respondents, most (68.0 %) would have their child vaccinated against LD, with significantly more being willing in high compared to emerging incidence states (70.4 % versus 63.6 %, p = 0.027). Of parents who were unsure or unwilling, 33.5 % and 16.5 %, respectively, would do so with a provider recommendation. Vaccine safety concerns were among the top reasons for LD vaccine hesitancy. More parents preferred a pre-formed antibody (42.3 %) compared to a 3-dose vaccine series (34.7 %). Significant predictors of willingness to have one's child vaccinated were higher parental education; higher perceived risk of child getting LD; child spending time outdoors daily or weekly; following a regular vaccine schedule; and positive attitude towards vaccines. Significant predictors of preference for monoclonal antibody over a 3-dose vaccine series included prior awareness of LD, living in a rural area, and less positive attitudes towards vaccines.
Conclusions: Two-thirds of parents in high and emerging incidence states would vaccinate their children against Lyme disease. Addressing safety concerns will be important, and a health care provider recommendation could also encourage those who are unsure or unwilling. Given the slight preference for monoclonal antibody over vaccine, particularly in rural areas, access to both may increase LD prevention.
Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Courtney Gidengil reports financial support was provided by Centers for Disease Control and Prevention. I have served as an ad hoc reviewer for manuscripts submitted to Vaccine in the past. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 RAND Corporation. Published by Elsevier Ltd.. All rights reserved.)

المؤلفون: Courville JM; Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada., Czuzoj-Shulman N; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada., Spence AR; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada., Abenhaim HA; Department of Obstetrics and Gynecology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.; Center for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, Quebec, Canada.

المصدر: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics [Int J Gynaecol Obstet] 2024 Jul; Vol. 166 (1), pp. 451-457. Date of Electronic Publication: 2024 Jan 21.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0210174 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3479 (Electronic) Linking ISSN: 00207292 NLM ISO Abbreviation: Int J Gynaecol Obstet Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Pregnancy Complications, Infectious*/epidemiology , Pregnancy Outcome*/epidemiology, Humans ; Female ; Pregnancy ; Adult ; Retrospective Studies ; Infant, Newborn ; United States/epidemiology ; Incidence ; Young Adult ; Abruptio Placentae/epidemiology ; Premature Birth/epidemiology

مستخلص: Objective: The incidence of Lyme disease (LD) infections has risen in recent decades. Gestational LD has been associated with adverse pregnancy outcomes; however, the results have been contradictory. The study objective was to examine the effects of gestational LD on obstetrical and neonatal outcomes.
Methods: Using the Healthcare Cost & Utilization Project National (Nationwide) Inpatient Sample from the United States, we conducted a retrospective cohort study of pregnant patients admitted to the hospital between 2016 and 2019. The exposed group consisted of pregnant patients with gestational LD infection (International Classification of Diseases, Tenth Revision [ICD-10] code A692x), while the comparison group consisted of pregnant patients without gestational LD. Descriptive statistics and multivariate logistic regression models, adjusted for baseline maternal characteristics, were used to determine the associations between gestational LD and obstetrical and neonatal outcomes.
Results: The cohort included 2 943 575 women, 226 of whom were diagnosed with LD during pregnancy. The incidence of LD was 7.67 per 100 000 pregnancy admissions. The incidence of gestational LD was stable over the study period. Pregnant patients with LD were more likely white, older, to have private health insurance, and to belong to a higher income quartile. Gestational LD was associated with an increased risk of placental abruption (adjusted odds ratio [aOR], 3.45 [95% confidence interval (CI), 1.53-7.80]) and preterm birth (aOR, 1.58 [95% CI, 1.03-2.42]).
Conclusion: Gestational LD is associated with a higher risk of placental abruption and preterm birth. Pregnancies complicated by LD, while associated with a higher risk of certain adverse outcomes, can be followed in most healthcare settings.
(© 2024 International Federation of Gynecology and Obstetrics.)

المؤلفون: Lantos PM; Duke University School of Medicine, Durham, NC, United States of America.; Duke Global Health Institute, Durham, NC, United States of America., Janko M; Duke Global Health Institute, Durham, NC, United States of America., Nigrovic LE; Boston Children's Hospital, Boston, MA, United States of America., Ruffin F; Duke University School of Medicine, Durham, NC, United States of America., Kobayashi T; University of Iowa Hospital and Clinics, Iowa City, IA, United States of America., Higgins Y; Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America., Auwaerter PG; Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.

المصدر: PloS one [PLoS One] 2024 May 31; Vol. 19 (5), pp. e0301530. Date of Electronic Publication: 2024 May 31 (Print Publication: 2024).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Lyme Disease*/diagnosis, Humans ; Female ; Male ; Middle Aged ; Adult ; Bayes Theorem ; Electronic Health Records ; United States/epidemiology ; Aged ; Mid-Atlantic Region/epidemiology ; Adolescent ; Young Adult ; Child ; Maryland/epidemiology

مستخلص: Lyme disease is a spatially heterogeneous tick-borne infection, with approximately 85% of US cases concentrated in the mid-Atlantic and northeastern states. Surveillance for Lyme disease and its causative agent, including public health case reporting and entomologic surveillance, is necessary to understand its endemic range, but currently used case detection methods have limitations. To evaluate an alternative approach to Lyme disease surveillance, we have performed a geospatial analysis of Lyme disease cases from the Johns Hopkins Health System in Maryland. We used two sources of cases: a) individuals with both a positive test for Lyme disease and a contemporaneous diagnostic code consistent with a Lyme disease-related syndrome; and b) individuals referred for a Lyme disease evaluation who were adjudicated to have Lyme disease. Controls were individuals from the referral cohort judged not to have Lyme disease. Residential address data were available for all cases and controls. We used a hierarchical Bayesian model with a smoothing function for a coordinate location to evaluate the probability of Lyme disease within 100 km of Johns Hopkins Hospital. We found that the probability of Lyme disease was greatest in the north and west of Baltimore, and the local probability that a subject would have Lyme disease varied by as much as 30-fold. Adjustment for demographic and ecological variables partially attenuated the spatial gradient. Our study supports the suitability of electronic medical record data for the retrospective surveillance of Lyme disease.
Competing Interests: The authors have declared that no competing interests exist.
(Copyright: © 2024 Lantos et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

المؤلفون: Eisen L; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, United States. Electronic address: evp4@cdc.gov., Saunders MEM; Vector-Borne Disease Section, California Department of Public Health, 1616 Capitol Ave, Sacramento, CA 95814, United States., Kramer VL; Vector-Borne Disease Section, California Department of Public Health, 1616 Capitol Ave, Sacramento, CA 95814, United States., Eisen RJ; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, United States.

المصدر: Ticks and tick-borne diseases [Ticks Tick Borne Dis] 2024 May; Vol. 15 (3), pp. 102325. Date of Electronic Publication: 2024 Feb 21.

نوع المنشور: Journal Article; Review

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101522599 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1877-9603 (Electronic) Linking ISSN: 1877959X NLM ISO Abbreviation: Ticks Tick Borne Dis Subsets: MEDLINE

مواضيع طبية MeSH: Ixodes* , Deer* , Lyme Disease*/epidemiology , Borrelia burgdorferi*, Humans ; United States/epidemiology ; Animals ; Washington

مستخلص: Ixodes pacificus (the western blacklegged tick) occurs in the far western United States (US), where it commonly bites humans. This tick was not considered a species of medical concern until it was implicated in the 1980s as a vector of Lyme disease spirochetes. Later, it was discovered to also be the primary vector to humans in the far western US of agents causing anaplasmosis and hard tick relapsing fever. The core distribution of I. pacificus in the US includes California, western Oregon, and western Washington, with outlier populations reported in Utah and Arizona. In this review, we provide a history of the documented occurrence of I. pacificus in the US from the 1890s to present, and discuss associations of its geographic range with landscape, hosts, and climate. In contrast to Ixodes scapularis (the blacklegged tick) in the eastern US, there is no evidence for a dramatic change in the geographic distribution of I. pacificus over the last half-century. Field surveys in the 1930s and 1940s documented I. pacificus along the Pacific Coast from southern California to northern Washington, in the Sierra Nevada foothills, and in western Utah. County level collection records often included both immatures and adults of I. pacificus, recovered by drag sampling or from humans, domestic animals, and wildlife. The estimated geographic distribution presented for I. pacificus in 1945 by Bishopp and Trembley is similar to that presented in 2022 by the Centers for Disease Control and Prevention. There is no clear evidence of range expansion for I. pacificus, separate from tick records in new areas that could have resulted from newly initiated or intensified surveillance efforts. Moreover, there is no evidence from long-term studies that the density of questing I. pacificus ticks has increased over time in specific areas. It therefore is not surprising that the incidence of Lyme disease has remained stable in the Pacific Coast states from the early 1990s, when it became a notifiable condition, to present. We note that deforestation and deer depredation were less severe in the far western US during the 1800s and early 1900s compared to the eastern US. This likely contributed to I. pacificus maintaining stable, widespread populations across its geographic range in the far western US in the early 1900s, while I. scapularis during the same time period appears to have been restricted to a small number of geographically isolated refugia sites within its present range in the eastern US. The impact that a warming climate may have had on the geographic distribution and local abundance of I. pacificus in recent decades remains unclear.
Competing Interests: Declaration of competing interest None
(Published by Elsevier GmbH.)

المؤلفون: Foster E; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, Fort Collins 80521, CO, USA. Electronic address: owm1@cdc.gov., Holcomb KM; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, Fort Collins 80521, CO, USA., Eisen RJ; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, 3156 Rampart Road, Fort Collins, CO 80521, Fort Collins 80521, CO, USA.

المصدر: Ticks and tick-borne diseases [Ticks Tick Borne Dis] 2024 May; Vol. 15 (3), pp. 102316. Date of Electronic Publication: 2024 Feb 06.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101522599 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1877-9603 (Electronic) Linking ISSN: 1877959X NLM ISO Abbreviation: Ticks Tick Borne Dis Subsets: MEDLINE

مواضيع طبية MeSH: Ixodes* , Lyme Disease*/epidemiology , Tick Bites* , Borrelia burgdorferi*, United States/epidemiology ; Animals ; Environment ; Nymph

مستخلص: The majority of vector-borne disease cases reported annually in the United States are caused by pathogens spread by the blacklegged tick, Ixodes scapularis. The number and geographic distribution of cases have increased as the geographic range and abundance of the tick have expanded in recent decades. A large proportion of Lyme disease and other I. scapularis-borne diseases are associated with nymphal tick bites; likelihood of such bites generally increases with increasing nymphal densities. National tick surveillance was initiated in 2018 to track changes in the distribution and abundance of medically important ticks at the county spatial scale throughout the United States. Tick surveillance records, including historical data collected prior to the initiation of the national program, are collated in the ArboNET Tick Module database. Through exploration of ArboNET Tick Module data, we found that efforts to quantify the density of host-seeking I. scapularis nymphs (DON) were unevenly distributed among geographic regions with the greatest proportion of counties sampled in the Northeast and Upper Midwest. Submissions covering tick collections from 2004 through 2022 revealed extensive variation in DON estimates at collection site, county, state, and regional spatial scales. Throughout the entire study period, county DON estimates ranged from 0.0 to 488.5 nymphs/1,000 m ² . Although substantial variation was recorded within regions, DON estimates were greatest in the Northeast, Upper Midwest, and northern states within the Southeast regions (Virginia and North Carolina); densities were intermediate in the Ohio Valley and very low in the South and Northern Rockies and Plains regions. The proportion of counties classified as moderate or high DON was lower in the Northeast, Ohio Valley, and Southeast regions during the 2004 through 2017 time period (prior to initiation of the national tick surveillance program) compared to 2018 through 2022; DON estimates remained similarly low between these time periods in the South and the Northern Rockies and Plains regions. Despite the limitations described herein, the ArboNET Tick Module provides useful data for tracking changes in acarological risk across multiple geographic scales and long periods of time.
Competing Interests: Declaration of competing interests None.
(Published by Elsevier GmbH.)

المؤلفون: Kapoor T; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Murray L; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., Kuvaldina M; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., Jiang CS; Department of Hospital Biostatistics, The Rockefeller University, New York, New York, USA., Peace AA; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA., Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Jurado A; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA., Robbiani DF; Laboratory of Molecular Immunology, The Rockefeller University, New York, New York, USA., Klemens O; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany., Lattwein E; Institute for Experimental Immunology, affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, Germany., Sabalza M; EUROIMMUN US, Mountain Lakes, New Jersey, USA., Fallon BA; Department of Psychiatry, Columbia University, and New York State Psychiatric Institute, New York, New York, USA., MacDonald MR; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, New York, USA.

المصدر: Vector borne and zoonotic diseases (Larchmont, N.Y.) [Vector Borne Zoonotic Dis] 2024 Apr; Vol. 24 (4), pp. 226-236. Date of Electronic Publication: 2024 Mar 01.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100965525 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-7759 (Electronic) Linking ISSN: 15303667 NLM ISO Abbreviation: Vector Borne Zoonotic Dis Subsets: MEDLINE

مواضيع طبية MeSH: Encephalitis Viruses, Tick-Borne* , Encephalitis, Tick-Borne*/veterinary , Lyme Disease*/epidemiology , Lyme Disease*/veterinary , Ixodes*, Animals ; Humans ; United States/epidemiology ; Prevalence ; Retrospective Studies ; Prospective Studies ; New England/epidemiology ; Antibodies, Viral ; Immunoglobulin G

مستخلص: Introduction: Lyme disease (LD) affects ∼476,000 people each year in the United States. Symptoms are variable and include rash and flu-like symptoms. Reasons for the wide variation in disease outcomes are unknown. Powassan virus (POWV) is a tick-borne flavivirus that causes disease ranging from asymptomatic infection to encephalitis, neurologic damage, and death. POWV and LD geographic case distributions overlap, with Ixodes species ticks as the common vectors. Clinical ramifications of coinfection or sequential infection are unknown. Objectives: This study's primary objective was to determine the prevalence of POWV-reactive antibodies in sera samples collected from previously studied cohorts of individuals with self-reported LD history residing in the Northeastern United States. As a secondary objective, we studied clinical differences between people with self-reported LD history and low versus high POWV antibody levels. Methods: We used an enzyme-linked immunosorbent assay (ELISA) to quantify IgG directed at the POWV envelope (E) protein domain III in 538 samples from individuals with self-reported LD history and 16 community controls. The samples were also tested with an ELISA assay to quantify IgG directed at the POWV NS1 protein. Results: The percentage of individuals with LD history and possible evidence of POWV exposure varied depending on the assay utilized. We found no significant difference in clinical symptoms between those with low or high POWV IgG levels in the in-house assay. Congruence of the EDIII and NS1 assays was low with only 12% of those positive in the in-house EDIII ELISA testing positive in the POWV NS1 ELISA. Conclusions: The results highlight the difficulty in flavivirus diagnostic testing, particularly in the retrospective detection of flavivirus exposure. The findings suggest that a prospective study with symptomatic patients using approved clinical testing is necessary to address the incidence and clinical implications of LD and POWV co-infection or sequential infection.

المؤلفون: Yang H; Abt Associates, 6130 Executive Boulevard, Rockville, MD, 2085, USA., Gould CA; Climate Change Division, Climate Science and Imapcts Branch, U.S. Environmental Protection Agency, 1200 Pennsylvania Ave NW, 4226-G South, Washington, DC, 20460, USA. gould.caitlin@epa.gov., Jones R; Abt Associates, 6130 Executive Boulevard, Rockville, MD, 2085, USA., St Juliana A; Abt Associates, 6130 Executive Boulevard, Rockville, MD, 2085, USA., Sarofim M; Climate Change Division, Climate Science and Imapcts Branch, U.S. Environmental Protection Agency, 1200 Pennsylvania Ave NW, 4226-G South, Washington, DC, 20460, USA., Rissing M; Abt Associates, 6130 Executive Boulevard, Rockville, MD, 2085, USA., Hahn MB; Institute for Circumpolar Health Studies, University of Alaska-Anchorage, 3211 Providence Drive, Anchorage, AK, 99508, USA.

المصدر: EcoHealth [Ecohealth] 2024 Mar; Vol. 21 (1), pp. 56-70. Date of Electronic Publication: 2024 Mar 13.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Springer Country of Publication: United States NLM ID: 101222144 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1612-9210 (Electronic) Linking ISSN: 16129202 NLM ISO Abbreviation: Ecohealth Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/epidemiology , Lyme Disease*/economics , Ixodes*/microbiology , Climate Change* , Borrelia burgdorferi*, Humans ; Animals ; Midwestern United States/epidemiology ; Incidence ; United States/epidemiology ; Ecosystem

مستخلص: Lyme disease (LD) is the most common vector-borne disease in the United States (U.S.). This paper assesses how climate change may influence LD incidence in the eastern and upper Midwestern U.S. and the associated economic burden. We estimated future Ixodes scapularis habitat suitability and LD incidence with a by-degree approach using variables from an ensemble of multiple climate models. We then applied estimates for present-day and projected habitat suitability for I. scapularis, present-day presence of Borrelia burgdorferi, and projected climatological variables to model reported LD incidence at the county level among adults, children, and the total population. Finally, we applied an estimate of healthcare expenses to project economic impacts. We show an overall increase in LD cases with regional variation. We estimate an increase in incidence in New England and the upper Midwestern U.S. and a concurrent decrease in incidence in Virginia and North Carolina. At 3°C of national warming from the 1986-2015 baseline climate, we project approximately 55,000 LD cases, a 38-percent increase from present-day estimates. At 6°C of warming, our most extreme scenario, we project approximately 92,000 LD cases in the region, an increase of 145 percent relative to current levels. Annual LD-related healthcare expenses at 3°C of warming are estimated to be $236 million (2021 dollars), approximately 38 percent greater than present-day. These results may inform decision-makers tasked with addressing climate risks, the public, and healthcare professionals preparing for treatment and prevention of LD.
(© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)

المؤلفون: Kugeler KJ; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC., Earley A; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC., Mead PS; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC., Hinckley AF; Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC.

المصدر: MMWR. Morbidity and mortality weekly report [MMWR Morb Mortal Wkly Rep] 2024 Feb 15; Vol. 73 (6), pp. 118-123. Date of Electronic Publication: 2024 Feb 15.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: U.S. Centers for Disease Control Country of Publication: United States NLM ID: 7802429 Publication Model: Electronic Cited Medium: Internet ISSN: 1545-861X (Electronic) Linking ISSN: 01492195 NLM ISO Abbreviation: MMWR Morb Mortal Wkly Rep Subsets: MEDLINE

مواضيع طبية MeSH: Lyme Disease*/diagnosis , Lyme Disease*/epidemiology, Adult ; Animals ; United States/epidemiology ; Humans ; Aged ; Zoonoses ; Incidence ; Laboratories

مستخلص: Lyme disease, a tickborne zoonosis caused by certain species of Borrelia spirochetes, is the most common vectorborne disease in the United States. Approximately 90% of all cases are reported from 15 high-incidence jurisdictions in the Northeast, mid-Atlantic, and upper-Midwest regions. After the implementation of a revised surveillance case definition in 2022, high-incidence jurisdictions report cases based on laboratory evidence alone, without need for additional clinical information. In 2022, 62,551 Lyme disease cases were reported to CDC, 1.7 times the annual average of 37,118 cases reported during 2017-2019. Annual incidence increased most in older age groups, with incidence among adults aged ≥65 years approximately double that during 2017-2019. The sharp increase in reported Lyme disease cases in 2022 likely reflects changes in surveillance methods rather than change in disease risk. Although these changes improve standardization of surveillance across jurisdictions, they preclude detailed comparison with historical data.
Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.